Relmada Therapeutics: Run Up Into Results May Resume Following This Drop [Seeking Alpha]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Seeking Alpha
The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged. RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin. With full-year 2023 earnings, Relmada Therapeutics ( NASDAQ: RLMD ) has announced it intends to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2'2024. I haven't written about RLMD since September 2023, when I noted a run up into phase 3 results was possible and could be enhanced by a possible interim readout, rating it a strong buy. In this article I take a look at recent updates and price action, to consider what the stock might do next. Run up into Reliance II results? RLMD is up about 20% since my previous article, but it isn't clear how much of that is simply due to a rally in biotech, with RLMD representin
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsPR Newswire
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024PR Newswire
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 3/19/24 - Beat
RLMD
Sec Filings
- 4/9/24 - Form DEFA14A
- 4/9/24 - Form DEF
- 3/19/24 - Form 8-K
- RLMD's page on the SEC website